Marketing-authorisation holder
Astellas Pharma
60 medicines in 2 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
60 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 60
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADENOCARD3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Adenosine | United States | Not marketed | 1989 |
| ADENOSCAN60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 90MG/30ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Adenosine | United States | Not marketed | 1995 |
| AMBISOME50mg/vial · Injectable, liposomal | Amphotericin b | United States | Marketed | 1997 |
| ARISTOCORT0.1% | 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOCORT16mg | 1mg | 2mg | 4mg | 8mg · Tablet | Triamcinolone | United States | Not marketed | 1957 |
| ARISTOCORT0.025% | 0.1% | 0.5% · Cream | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOCORT2mg/5ml · Syrup | Triamcinolone | United States | Not marketed | 1959 |
| ARISTOCORT A0.1% | 0.5% | 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOCORT A0.025% | 0.1% | 0.5% · Cream | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOGEL0.1% · GEL | Triamcinolone | United States | Not marketed | 1973 |
| ASTAGRAF XL0.5mg base | 1mg base | 5mg base · Capsule, extended release | Tacrolimus | United States | Marketed | 2013 |
| CEFIZOX10gm base/vial | 1gm base/vial | 2gm base/vial | 500mg base/vial · Injectable | Ceftizoxime | United States | Not marketed | 1983 |
| CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER20mg base/ml | 40mg base/ml · Injectable | Ceftizoxime | United States | Not marketed | 1984 |
| CEFIZOX IN PLASTIC CONTAINER20mg base/ml | 40mg base/ml · Injectable | Ceftizoxime | United States | Not marketed | 1984 |
| CRESEMBA372mg · Powder | Isavuconazole | United States | Marketed | 2015 |
| CRESEMBA186mg | 74.5mg · Capsule | Isavuconazole | United States | Marketed | 2015 |
| CYCLOCORT0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Cream | Amcinonide | United States | Not marketed | 1979 |
| CYCLOCORT0.1% · Lotion | Amcinonide | United States | Not marketed | 1988 |
| CYCLOCORT0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Amcinonide | United States | Not marketed | 1981 |
| IZERVAY2mg base/0.1ml (eq 2mg base/0.1ml) · Solution | Avacincaptad pegol | United States | Marketed | 2023 |
| LEXISCAN0.4mg/5ml (0.08mg/ml) · Solution | Regadenoson | United States | Marketed | 2008 |
| MYCAMINE100mg base/vial | 50mg base/vial · Injectable | Micafungin | United States | Not marketed | 2005 |
| PADCEV20mg/vial | 30mg/vial · Injectable | Enfortumab vedotin | United States | Marketed | 2019 |
| PROGRAF0.2mg base/packet | 1mg base/packet · For suspension | Tacrolimus | United States | Marketed | 2018 |
| PROGRAF0.5mg base | 1mg base | 5mg base · Capsule | Tacrolimus | United States | Marketed | 1994 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 36 | 34 | 2 | CompaniesAll medicines |
| Saudi Arabia | 24 | 24 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.